Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model

Barbara Bedogni, Scott Welford, Andrea C. Kwan, James Ranger-Moore, Kathylynn Saboda, Marianne Broome Powell

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

A number of human melanomas show hyperactivation of the Ras pathway due to mutations of the molecule or alteration of upstream or downstream effectors. In this study, we evaluated the effect of blocking the two Ras downstream pathways phosphatidylinositol-3-kinase/Akt and Raf/ mitogen-activated protein kinase kinase/extracellular signal-regulated kinase on melanoma development and regression in the TPRas mouse model. The inhibition of these two signaling cascades by topically applied Ly294002 and U0126 significantly delayed melanoma development and significantly decreased the tumor incidence, particularly when the drugs were applied in combination. Treatment with the inhibitors of established melanomas resulted in complete remission in 33% of mice and partial regression in 46% of mice when drugs were delivered in combination. These responses correlated with increased apoptosis and decreased proliferation both in vitro and in vivo and reduced tumor angiogenesis. In conclusion, this study strongly supports the role of the phosphatidylinositol-3-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways in the development and maintenance of Ras-dependent melanomas and supports the notion that specific inhibition of these effectors may represent a very promising avenue for the treatment and prevention of the disease.

Original languageEnglish (US)
Pages (from-to)3071-3077
Number of pages7
JournalMolecular Cancer Therapeutics
Volume5
Issue number12
DOIs
StatePublished - Dec 1 2006
Externally publishedYes

Fingerprint

MAP Kinase Kinase 2
MAP Kinase Kinase 1
Phosphatidylinositol 3-Kinase
Transgenic Mice
Melanoma
Mitogen-Activated Protein Kinase Kinases
Extracellular Signal-Regulated MAP Kinases
Pharmaceutical Preparations
Neoplasms
Maintenance
Apoptosis
Mutation
Incidence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model. / Bedogni, Barbara; Welford, Scott; Kwan, Andrea C.; Ranger-Moore, James; Saboda, Kathylynn; Powell, Marianne Broome.

In: Molecular Cancer Therapeutics, Vol. 5, No. 12, 01.12.2006, p. 3071-3077.

Research output: Contribution to journalArticle

@article{0ea236449d2241b0ac8ff1b6d9a73884,
title = "Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model",
abstract = "A number of human melanomas show hyperactivation of the Ras pathway due to mutations of the molecule or alteration of upstream or downstream effectors. In this study, we evaluated the effect of blocking the two Ras downstream pathways phosphatidylinositol-3-kinase/Akt and Raf/ mitogen-activated protein kinase kinase/extracellular signal-regulated kinase on melanoma development and regression in the TPRas mouse model. The inhibition of these two signaling cascades by topically applied Ly294002 and U0126 significantly delayed melanoma development and significantly decreased the tumor incidence, particularly when the drugs were applied in combination. Treatment with the inhibitors of established melanomas resulted in complete remission in 33{\%} of mice and partial regression in 46{\%} of mice when drugs were delivered in combination. These responses correlated with increased apoptosis and decreased proliferation both in vitro and in vivo and reduced tumor angiogenesis. In conclusion, this study strongly supports the role of the phosphatidylinositol-3-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways in the development and maintenance of Ras-dependent melanomas and supports the notion that specific inhibition of these effectors may represent a very promising avenue for the treatment and prevention of the disease.",
author = "Barbara Bedogni and Scott Welford and Kwan, {Andrea C.} and James Ranger-Moore and Kathylynn Saboda and Powell, {Marianne Broome}",
year = "2006",
month = "12",
day = "1",
doi = "10.1158/1535-7163.MCT-06-0269",
language = "English (US)",
volume = "5",
pages = "3071--3077",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model

AU - Bedogni, Barbara

AU - Welford, Scott

AU - Kwan, Andrea C.

AU - Ranger-Moore, James

AU - Saboda, Kathylynn

AU - Powell, Marianne Broome

PY - 2006/12/1

Y1 - 2006/12/1

N2 - A number of human melanomas show hyperactivation of the Ras pathway due to mutations of the molecule or alteration of upstream or downstream effectors. In this study, we evaluated the effect of blocking the two Ras downstream pathways phosphatidylinositol-3-kinase/Akt and Raf/ mitogen-activated protein kinase kinase/extracellular signal-regulated kinase on melanoma development and regression in the TPRas mouse model. The inhibition of these two signaling cascades by topically applied Ly294002 and U0126 significantly delayed melanoma development and significantly decreased the tumor incidence, particularly when the drugs were applied in combination. Treatment with the inhibitors of established melanomas resulted in complete remission in 33% of mice and partial regression in 46% of mice when drugs were delivered in combination. These responses correlated with increased apoptosis and decreased proliferation both in vitro and in vivo and reduced tumor angiogenesis. In conclusion, this study strongly supports the role of the phosphatidylinositol-3-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways in the development and maintenance of Ras-dependent melanomas and supports the notion that specific inhibition of these effectors may represent a very promising avenue for the treatment and prevention of the disease.

AB - A number of human melanomas show hyperactivation of the Ras pathway due to mutations of the molecule or alteration of upstream or downstream effectors. In this study, we evaluated the effect of blocking the two Ras downstream pathways phosphatidylinositol-3-kinase/Akt and Raf/ mitogen-activated protein kinase kinase/extracellular signal-regulated kinase on melanoma development and regression in the TPRas mouse model. The inhibition of these two signaling cascades by topically applied Ly294002 and U0126 significantly delayed melanoma development and significantly decreased the tumor incidence, particularly when the drugs were applied in combination. Treatment with the inhibitors of established melanomas resulted in complete remission in 33% of mice and partial regression in 46% of mice when drugs were delivered in combination. These responses correlated with increased apoptosis and decreased proliferation both in vitro and in vivo and reduced tumor angiogenesis. In conclusion, this study strongly supports the role of the phosphatidylinositol-3-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways in the development and maintenance of Ras-dependent melanomas and supports the notion that specific inhibition of these effectors may represent a very promising avenue for the treatment and prevention of the disease.

UR - http://www.scopus.com/inward/record.url?scp=33846230965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846230965&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-06-0269

DO - 10.1158/1535-7163.MCT-06-0269

M3 - Article

C2 - 17172409

AN - SCOPUS:33846230965

VL - 5

SP - 3071

EP - 3077

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 12

ER -